About Eidos Therapeutics, Inc.

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

At the moment the company generates 27M USD in revenues.

On its last earning announcement, the company reported a loss of -0.55$ per share.

The book value per share is 4.37$

Eidos Therapeutics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
27M - -32M -119.30% -36M -0.55 - - 36M 4.37 -25M - -25M